Humanitarian use licenses

Cerecin strengthens position in neurometabolism with addition to pipeline

Retrieved on: 
Tuesday, September 19, 2023
Epilepsy, Heart, Patent, Migraine, Partnership, University, Diabetes, Cancer, Spasm, PET, Brain, Cell, Ketosis, Molecular imaging, Isotope, Alzheimer's disease, Humanitarian use licenses, Disease, Medical imaging, Pharmaceutical industry

DENVER, Colo. and SINGAPORE, Sept. 19, 2023 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the in-license of CER-022 from the University of Alberta.

Key Points: 
  • DENVER, Colo. and SINGAPORE, Sept. 19, 2023 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the in-license of CER-022 from the University of Alberta.
  • The in-license is part of Cerecin's pipeline expansion and further strengthens its position as a leader in neurometabolism, addressing metabolic targets and bioenergetics in disease.
  • CER-022 is an 18Fluorinated beta-hydroxybutyrate ([18F]FBHB) for investigational use in positron emission tomography (PET) studies of ketone body metabolism.
  • 16/992,940, title:  Fluorinated beta-hydroxybutyric acids for PET imaging, licensed to Cerecin by the University of Alberta.

Kinarus Therapeutics Announces Personnel Changes

Retrieved on: 
Wednesday, July 12, 2023
Drug development, Probability, Therapy, Hangzhou, SIX Swiss Exchange, Exchange, Financial audit, KNRS, Patent, CFO, Knowledge, API, IPF, Pioglitazone, Humanitarian use licenses, MAP, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.

Key Points: 
  • Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets.
  • His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.

Kinarus Therapeutics Announces Personnel Change

Retrieved on: 
Wednesday, July 12, 2023
Drug development, Probability, Therapy, Hangzhou, SIX Swiss Exchange, Exchange, Financial audit, KNRS, Patent, CFO, Knowledge, API, IPF, Pioglitazone, Humanitarian use licenses, MAP, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.

Key Points: 
  • Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets.
  • His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.

IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

Retrieved on: 
Tuesday, July 11, 2023
Reichmann, Infection, Asthma, Series, Interview, Macular degeneration, COVID-19, BVXV, Inflammation, Psoriasis, Patient, Autoimmune disease, Steroid, Podcast, Single-domain antibody, Interleukin, Letter, Max Planck Society, Humanitarian use licenses, IBN, Conditional sentence, Pharmaceutical industry

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.

Key Points: 
  • The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.
  • Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) .
  • To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year.
  • The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series .

Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity

Retrieved on: 
Tuesday, June 27, 2023
Knowledge, Drug development, Probability, Pioglitazone, Therapy, Humanitarian use licenses, Hangzhou, KNRS, Muthiri kinaru

Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian (Hangzhou) Investment Management Co (CDIM), in Kinarus.

Key Points: 
  • Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian (Hangzhou) Investment Management Co (CDIM), in Kinarus.
  • The bridge loans are immediately available and Kinarus can decide when to request delivery of funds, , depending on the settlement of the funds to be transfer from CDIM.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “While CDIM’s commitment to Kinarus has not waivered, there are customary bureaucratic and regulatory processes that need to be respected when Chinese groups invest abroad.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management

Retrieved on: 
Thursday, May 11, 2023
MAP, Idiopathic disease, Partnership, Idiopathic pulmonary fibrosis, Drug development, Therapy, Probability, Hangzhou, AMD, KNRS, HIV disease progression rates, Patent, Patient, Disease, Knowledge, Mortality, API, IPF, Pioglitazone, CHF, Humanitarian use licenses, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China (“CDIM”).

Key Points: 
  • Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China (“CDIM”).
  • Under the terms of the loan agreement, CDIM grants a subordinated loan in the amount of CHF 1.5 million to Kinarus for a fixed term of three years without any interest.
  • During the term of the agreement, the outstanding loan amount can be converted at any time into Kinarus shares with a nominal value of CHF 0.01 at a fixed conversion price of CHF 0.01 per Kinarus share.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Mydecine Innovations Group Provides Corporate Update

Retrieved on: 
Monday, April 3, 2023
Intellectual property, Drug development, Quality of life, Edinburgh Capitals, Politics, IP, Princeton University, Patient, OTC, Mental health, NEO, ChromeOS, Humanitarian use licenses, PTSD, Pharmaceutical industry, Fine chemical

Mydecine continues to focus on the success of the Company and creating value for its shareholders.

Key Points: 
  • Mydecine continues to focus on the success of the Company and creating value for its shareholders.
  • With its innovative IP portfolio, groundbreaking research, and unwavering commitment to improving patients' lives, Mydecine is poised to become a significant partner in the biopharmaceutical industry.
  • In his place, Mydecine announces that Neil Stevenson-Moore has been appointed as an independent Director to the Board and audit committee member effective today.
  • He has an impressive track record of driving growth, success and innovation and has worked in both corporate and entrepreneurial environments.

CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022

Retrieved on: 
Friday, March 31, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, IPO, Glycogen storage disease type II, American Society of Gene and Cell Therapy, Congress, Investigational New Drug, Patient, MG, Cell, IBAT, Enzyme replacement therapy, Fabry disease, DSM-IV codes, University of Massachusetts, Gene, Food, GD, Glioblastoma, Paroxysmal nocturnal hemoglobinuria, ESGCT, Rare, FDA, IND, Safety, COVID-19, MPS II, Myasthenia gravis, MPS, AAV, PNH, Alexion, Alagille syndrome, Hunter syndrome, Gene therapy, SMA, Liver disease, Clinical trial, NDA, Part, Catholic Medical Mission Board, ERT, Mouse, European Society for Primary Immunodeficiencies, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Humanitarian use licenses, European Society of Gene and Cell Therapy, Pharmaceutical industry, Cryptocurrency, Vaccine, Fabry, C5

CANbridge Pharmaceuticals, Inc. (“CANbridge,” stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, today announced financial results for the twelve months ended 2022 and corporate update.

Key Points: 
  • CANbridge Pharmaceuticals, Inc. (“CANbridge,” stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, today announced financial results for the twelve months ended 2022 and corporate update.
  • The adjusted loss for the year decreased by RMB124.6 million, or 21.4%, from RMB581.3 million, for the year ended December 31, 2021, to RMB456.7 million for the year ended December 31, 2022.
  • R&D expense excluding milestone payments increased by RMB37.8 million, from RMB213.9 million for the year ended December 31, 2021 to RMB251.7 million for the year ended December 31, 2022.
  • CANbridge completed the full technology transfer of these gene therapy products in late 2022.

IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes

Retrieved on: 
Friday, March 3, 2023
Research, Patent, MBA, Pharmacology, Michael J. Freeman, IBN, Max Planck Society, Vaccine, IP, Mitsubishi Tanabe Pharma, BiondVax, The Michael J. Fox Foundation, Running, Humanitarian use licenses, III, Engineering, BVXV, Diagnosis, Biotechnology, Skin, Reichmann, Entrepreneurship, Interview, Pharmaceutical industry, Test

Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale.

Key Points: 
  • Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale.
  • The broadcast, hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency , is available for on-demand listening on Test.
  • To begin the interview, Reichman discussed his professional journey leading up to joining BiondVax in 2021.
  • That was a very nice start to my career as an entrepreneur… I didn’t stay with NeuroDerm until the exit.

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

Retrieved on: 
Thursday, February 23, 2023
Biotechnology, Therapy, Cancer, Association of British HealthTech Industries, Aggregate, First Round Capital, Humanitarian use licenses, Patient, Apoptosis, Induced cell cycle arrest, PLK1, Builder, Y Combinator, Machine learning, AML, VBL, Founders Fund, Pharmaceutical industry, Volasertib, Notability

Companies to host conference call today at 8:30 AM Eastern Time MODIIN, Israel and FOSTER CITY, Cal, Feb. 23, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, and Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced they have entered into a definitive merger agreement. The combined company will focus on the advancement of Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”) and therapeutic pipeline focused on cancer patients with high unmet medical needs. Immediately after the merger, Notable stockholders are expected to own approximately 76% and VBL Therapeutics shareholders are expected to own approximately 24% of the combined company, each on a fully-diluted basis and subject to adjustment. The combined company is expected to operate under the name Notable Labs, Ltd. with its shares listed on the Nasdaq Capital Market under the ticker symbol ‘NTBL.’

Key Points: 
  • Immediately after the merger, Notable stockholders are expected to own approximately 76% and VBL Therapeutics shareholders are expected to own approximately 24% of the combined company, each on a fully-diluted basis and subject to adjustment.
  • PPMP has guided Notable in the selection and development of two clinical-stage therapeutic candidates in platform-predicted responding patients with AML.
  • Concurrent with the execution of the merger agreement, a healthtech-focused investor syndicate, including existing Notable stockholders Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund, have entered into a definitive securities purchase agreement with Notable to invest $10.3 million in gross proceeds prior to the close of the proposed merger.
  • After completion of the merger, the combined company is expected to be capitalized with a cash runway into 2025.